MCID: HMT002
MIFTS: 65

Hematologic Cancer

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hematologic Cancer

MalaCards integrated aliases for Hematologic Cancer:

Name: Hematologic Cancer 11 53 14 36
Hematologic Neoplasms 43 71 75
Hematologic Neoplasm 11 28 5
Hematologic Malignancies 53 14
Hematopoietic and Lymphoid System Tumor 11
Malignant Hematopoietic Neoplasm 11
Hematopoietic Neoplasms 71
Hematologic Malignancy 11
Hematopoietic Neoplasm 11
Hematological Tumors 11
Hematopoietic Cancer 11
Hematopoietic Tumors 11
Blood Cancer 11
Liquid Tumor 71

Classifications:



External Ids:

Disease Ontology 11 DOID:2531
MeSH 43 D019337
NCIt 49 C27134
SNOMED-CT 68 414388001
ICD11 33 1510618119
UMLS 71 C0376544 C0376545 C3890429

Summaries for Hematologic Cancer

Disease Ontology: 11 An organ system cancer located in the hematological system that is characterized by uncontrolled cellular proliferation in blood, bone marrow and lymph nodes.

MalaCards based summary: Hematologic Cancer, also known as hematologic neoplasms, is related to aggressive systemic mastocytosis and essential thrombocythemia. An important gene associated with Hematologic Cancer is ETV6 (ETS Variant Transcription Factor 6), and among its related pathways/superpathways are Disease and ERK Signaling. The drugs Fentanyl and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia: 75 Tumors of the hematopoietic and lymphoid tissues (American English) or tumours of the haematopoietic and... more...

Related Diseases for Hematologic Cancer

Diseases related to Hematologic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 892)
# Related Disease Score Top Affiliating Genes
1 aggressive systemic mastocytosis 32.6 U2AF1 RUNX1 KIT JAK2 FLT3 CBL
2 essential thrombocythemia 32.5 U2AF1 MPL KIT JAK2 IL3 FLT3
3 mast cell neoplasm 32.4 U2AF1 KIT IL3 FLT3
4 central nervous system leukemia 32.4 KMT2A ETV6 ABL1
5 peripheral nervous system disease 31.5 U2AF1 MIR199A1 KIT JAK2 CSF3
6 acute myelomonocytic leukemia 31.4 RUNX1 KMT2A KIT FLT3 ETV6 CSF1R
7 leukemia, acute myeloid 31.4 U2AF1 RUNX1 NUP98 MPL MIR199A1 KMT2A
8 myelodysplastic syndrome 31.4 U2AF1 RUNX1 NUP98 MPL MIR199A1 KMT2A
9 childhood leukemia 31.4 U2AF1 NUP98 KMT2A KIT FLT3 ETV6
10 lymphoma, hodgkin, classic 31.3 PVT1 JAK2 IL3 CSF3
11 acute biphenotypic leukemia 31.3 U2AF1 KMT2A KIT FLT3 ETV6 ABL1
12 juvenile myelomonocytic leukemia 31.3 U2AF1 RUNX1 NUP98 KMT2A KIT JAK2
13 leukemia, acute lymphoblastic 31.2 XIST U2AF1 RUNX1 PTHLH MPL MIR199A1
14 acute promyelocytic leukemia 31.2 U2AF1 RUNX1 PVT1 NUP98 KMT2A KIT
15 leukemia 31.2 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
16 lymphoma, non-hodgkin, familial 31.2 U2AF1 MIR199A1 KMT2A JAK2 IL3 FLT3
17 leukemia, chronic myeloid 31.2 U2AF1 RUNX1 NUP98 MPL MIR199A1 KMT2A
18 thrombocytopenia 31.1 U2AF1 RUNX1 MPL KIT JAK2 IL3
19 chronic eosinophilic leukemia 31.1 U2AF1 MPL KIT JAK2 IL3 FLT3
20 skin disease 31.0 U2AF1 MIR199A1 KIT JAK2 IL3 CSF3
21 acute leukemia 31.0 RUNX1 NUP98 MPL KMT2A KIT JAK2
22 hypereosinophilic syndrome 31.0 KIT JAK2 IL3 ABL1
23 mastocytosis, cutaneous 31.0 U2AF1 KIT IL3
24 t-cell acute lymphoblastic leukemia 31.0 U2AF1 PTHLH NUP98 IL3 CBL ABL1
25 thrombocytosis 30.9 U2AF1 MPL JAK2 IL3 CSF3
26 neutropenia 30.9 MPL IL3 FLT3 CSF3
27 myeloid leukemia 30.9 U2AF1 RUNX1 NUP98 KMT2A KIT JAK2
28 myeloma, multiple 30.9 U2AF1 PVT1 PTHLH MIR199A1 JAK2 IL3
29 leukemia, chronic lymphocytic 30.9 U2AF1 MIR199A1 KMT2A KIT JAK2 FLT3
30 granulocytopenia 30.9 IL3 CSF3
31 chronic myelomonocytic leukemia 30.9 U2AF1 RUNX1 MPL KIT JAK2 IL3
32 monocytic leukemia 30.9 RUNX1 KMT2A CSF3
33 renal cell carcinoma, nonpapillary 30.9 U2AF1 PVT1 PTHLH MIR199A1 KIT FLT3
34 paroxysmal nocturnal hemoglobinuria 30.9 U2AF1 IL3 FLT3 CSF3
35 leukemia, acute monocytic 30.9 U2AF1 NUP98 KMT2A FLT3
36 acute megakaryocytic leukemia 30.9 U2AF1 RUNX1 NUP98 MPL KMT2A KIT
37 myeloproliferative neoplasm 30.9 U2AF1 RUNX1 MPL KMT2A KIT JAK2
38 deficiency anemia 30.9 U2AF1 MPL KIT JAK2 IL3 FLT3
39 blood platelet disease 30.9 U2AF1 RUNX1 MPL KIT JAK2 IL3
40 adult acute lymphocytic leukemia 30.8 KMT2A ETV6 ABL1
41 myelodysplastic/myeloproliferative neoplasm 30.8 U2AF1 KIT JAK2 FLT3 ETV6 CBL
42 myelofibrosis 30.8 U2AF1 RUNX1 MPL KIT JAK2 IL3
43 rasopathy 30.8 U2AF1 KIT JAK2 FLT3 ETV6 CBL
44 breast cancer 30.8 XIST PVT1 PTHLH MIR199A1 KIT JAK2
45 precursor t-cell acute lymphoblastic leukemia 30.7 RUNX1 NUP98 KMT2A FLT3 ETV6 ABL1
46 pancytopenia 30.7 U2AF1 RUNX1 MPL KMT2A KIT IL3
47 chronic neutrophilic leukemia 30.7 U2AF1 KMT2A JAK2 CSF3 ABL1
48 refractory anemia 30.7 MPL CSF3
49 systemic mastocytosis 30.7 U2AF1 KIT JAK2 CBL
50 mastocytosis 30.7 KIT JAK2 IL3 FLT3

Graphical network of the top 20 diseases related to Hematologic Cancer:



Diseases related to Hematologic Cancer

Symptoms & Phenotypes for Hematologic Cancer

GenomeRNAi Phenotypes related to Hematologic Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.47 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.47 ABL1 KIT CSF1R JAK2
3 Decreased substrate adherent cell growth GR00193-A-3 9.47 JAK2
4 Decreased substrate adherent cell growth GR00193-A-4 9.47 ABL1 FLT3 KIT

MGI Mouse Phenotypes related to Hematologic Cancer:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.27 ABL1 CBL CSF1R ETV6 FLT3 JAK2
2 immune system MP:0005387 10.22 ABL1 CBL CSF1R CSF3 ETV6 FLT3
3 cellular MP:0005384 10.21 ABL1 CBL CSF1R ETV6 FLT3 IL3
4 neoplasm MP:0002006 10.18 ETV6 FLT3 IL3 JAK2 KIT KMT2A
5 endocrine/exocrine gland MP:0005379 10.17 ABL1 CBL CSF1R ETV6 FLT3 IL3
6 normal MP:0002873 10.16 ABL1 CSF1R ETV6 JAK2 KIT KMT2A
7 no phenotypic analysis MP:0003012 10.1 CSF1R ETV6 FLT3 KIT KMT2A MIR199A1
8 liver/biliary system MP:0005370 10.08 ABL1 CBL ETV6 JAK2 KIT KMT2A
9 embryo MP:0005380 10.06 ABL1 ETV6 JAK2 KIT KMT2A MPL
10 hematopoietic system MP:0005397 10.06 ABL1 CBL CSF1R CSF3 ETV6 FLT3
11 skeleton MP:0005390 10 ABL1 CBL CSF1R ETV6 FLT3 IL3
12 mortality/aging MP:0010768 9.86 ABL1 CBL CSF1R ETV6 FLT3 IL3
13 integument MP:0010771 9.32 CBL CSF1R CSF3 ETV6 JAK2 KIT

Drugs & Therapeutics for Hematologic Cancer

Drugs for Hematologic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 522)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
3
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
4
Colistin Approved Phase 4 1264-72-8, 1066-17-7 5311054
5
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415
6
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
7
Ribavirin Approved Phase 4 36791-04-5 37542
8
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130
9
Micafungin Approved, Investigational Phase 4 235114-32-6 477468
10
Ceftolozane Approved, Investigational Phase 4 689293-68-3 75984602
11
Tazobactam Approved Phase 4 89786-04-9 123630
12
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
13
Caspofungin Approved Phase 4 179463-17-3, 162808-62-0 2826718
14 Drotrecogin alfa activated Phase 4
15 Antiprotozoal Agents Phase 4
16 Antiparasitic Agents Phase 4
17 Antibodies, Anti-Idiotypic Phase 4
18 Narcotics Phase 4
19 Anesthetics, Intravenous Phase 4
20 Excitatory Amino Acid Antagonists Phase 4
21 Anesthetics, General Phase 4
22 Anesthetics, Dissociative Phase 4
23
Ketorolac Tromethamine Phase 4
24 Analgesics, Opioid Phase 4
25 Cilastatin, Imipenem Drug Combination Phase 4
26 Ceftolozane, tazobactam drug combination Phase 4
27 beta-Lactamase Inhibitors Phase 4
28 Hormones Phase 4
29 Hormone Antagonists Phase 4
30 Pharmaceutical Solutions Phase 4
31 Cytochrome P-450 Enzyme Inhibitors Phase 4
32 Cytochrome P-450 CYP3A Inhibitors Phase 4
33
Hydroxyitraconazole Phase 4 108222
34
Fludarabine Approved Phase 2, Phase 3 75607-67-9, 21679-14-1 30751 657237
35
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
36
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
37
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
38
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
39
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
40
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
41
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
42
Piperacillin Approved Phase 3 66258-76-2 43672
43
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
44
Fosaprepitant Approved Phase 3 172673-20-0 219090 135413538
45
Olanzapine Approved, Investigational Phase 3 132539-06-1 135398745 4585
46
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965
47
Vancomycin Approved Phase 3 1404-90-6 14969
48
Ibandronate Approved, Investigational Phase 3 114084-78-5 60852
49
Febuxostat Approved Phase 3 144060-53-7 134018
50
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2

Interventional clinical trials:

(show top 50) (show all 1235)
# Name Status NCT ID Phase Drugs
1 Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease Unknown status NCT03844360 Phase 4 Bortezomib;Eltrombopag;Imatinib;dasatinib;Pegaspargase;Anti-Infective Drugs;PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
2 Pilot Study About Viability and Efficacy of Intrabone Administration of Umbilical Cord Blood for Allogeneic Stem Cell Transplantation Unknown status NCT00838019 Phase 4
3 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
4 A Safety Evaluation of Xigris Drotrecogin Alfa Activated in Hematopoietic Stem Cell Transplant Patients With Severe Sepsis Completed NCT00067730 Phase 4 Drotrecogin Alfa (activated)
5 The Effect of Special Diets on Weight and Nutritional Intake in Haematological Cancer Patients Completed NCT02880709 Phase 4
6 Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults Completed NCT04952766 Phase 4
7 Analgesic Efficacy of Intra-muscular Ketamine-ketorolac Versus Fentanyl- Ketorolac for Children Undergoing Bone Marrow Biopsy and Aspiration Completed NCT03649334 Phase 4 ketamine-ketorolac;fentanyl- ketorolac
8 A Randomized Clinical Study of the Decolonization of MDR Gram-negative Bacteria in Patients With Haematological Malignancies Completed NCT02966457 Phase 4 Colistimethate Sodium
9 A Randomized Study Evaluating Two Different Schedules of Aerosolized Ribavirin For Treatment of RSV Upper Respiratory Infections in Patients With Hematological Malignancies Completed NCT00500578 Phase 4 Ribavirin
10 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial. Completed NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
11 A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area Completed NCT02372357 Phase 4 Posaconazole prophylaxis 120 mg/m² tid
12 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
13 Prospective, Observational and Cohort Clinical Research on Clinical Efficacy and Safety of Different Doses of Micafungin Sodium for Injection in Prevention and Treatment of Fungal Infection in Patients With Hematological Tumors Recruiting NCT04738955 Phase 4 Micafungin Sodium
14 Prospective, Single-arm, Multicenter Exploratory Clinical Study of the Combination of Etoposide, Cytarabine and PEG-rhG-CSF (EAP Regimen) on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological Malignancies Recruiting NCT05510089 Phase 4 Etoposide;Cytarabine;PEG-rhG-CSF
15 Human Papillomavirus Antibody Response After GARDASIL 9 Vaccination in Patients After Allogeneic Stem Cell Transplantation Active, not recruiting NCT03023631 Phase 4
16 CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients; a Single-arm, Single-center, Open-label Clinical Trial (CEF-10 Study) Not yet recruiting NCT05061654 Phase 4 Ceftolozane-tazobactam IV
17 A Multicenter, Randomized Trial Comparing The Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Subjects With Hematological Malignancy Terminated NCT02895529 Phase 4 Itraconazole;Caspofungin
18 Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC Unknown status NCT02944045 Phase 3 Methylprednisolone;Placebo
19 Stratégie Transfusionnelle érythrocytaire Dans la réanimation du Choc Septique du Patient d'Onco-hématologie : Essai randomisé Multicentrique TRANSPORT [TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock] Unknown status NCT03837171 Phase 3
20 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
21 Antibacterial Prophylaxis With Imipenem vs no Prophylaxis for Hematological Malignancies Patients Before Allogenetic Hematopoietic Stem Cell Transplantation Unknown status NCT03733340 Phase 2, Phase 3 Imipenem
22 Exercise During Chemotherapy for Patients With Hematological Malignancies Unknown status NCT00884364 Phase 3
23 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius
24 Evaluation of Benefit and Side Effects of Double Umbilical Cord Blood Units Stem Cell Transplantation in Hematologic Malignancies Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
25 Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care Completed NCT03483194 Phase 2, Phase 3 Kalinox
26 A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma Completed NCT00044759 Phase 3 Piperacillin/Tazobactam (Tazocin)
27 Platelet Transfusion Requirements in Hematopoietic Transplantation(PATH Pilot) Completed NCT02650791 Phase 3 Tranexamic Acid
28 Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens Completed NCT02635984 Phase 3 Olanzapine;Placebo
29 A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia Completed NCT03136445 Phase 3 Tranexamic acid (TXA).;Placebo
30 Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant Completed NCT00750737 Phase 3 Posaconazole;ABLC
31 Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation: The TRIST Study Completed NCT01237639 Phase 3
32 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients With Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01437787 Phase 3 SAR302503;Placebo
33 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy Completed NCT01254630 Phase 3
34 Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT03106662 Phase 3 cyclophosphamide administration
35 A Randomized, Controlled Study of Ibandronate for the Prevention of Bone Loss in Patients Who Have Received Allogeneic Bone Marrow Transplantation for Hematological Malignancies Completed NCT00824993 Phase 3 Ibandronate;Vitamin Supplements
36 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
37 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
38 Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol Completed NCT01724528 Phase 3 Febuxostat;Allopurinol
39 Mindfulness Meditation in Bone Marrow Transplantation Completed NCT00165282 Phase 2, Phase 3
40 Darbepoetin-alpha and i.v. Iron Administration After Autologous Hematopoietic Stem Cell Transplantation : a Prospective Randomized Trial Completed NCT00557817 Phase 2, Phase 3 Darbepoetin alpha (Aranesp);Iron saccharate (Venofer)
41 Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial Completed NCT00382759 Phase 2, Phase 3
42 A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®
43 Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
44 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
45 Pharmacologic Optimization of Voriconazole - a Prospective Clustered Group-randomized Cross-over Trial of Therapeutic Drug Monitoring Completed NCT00893555 Phase 3 voriconazole;voriconazole (dosing according to the SPC)
46 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT01530581 Phase 3
47 Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial Completed NCT02696408 Phase 3
48 A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies Completed NCT02566395 Phase 3 Cyclophosphamide
49 A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment Completed NCT01854567 Phase 3
50 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma Completed NCT01345019 Phase 3 Denosumab;Zoledronic acid;Placebo to Denosumab;Placebo to zoledronic acid;Denosumab (for the open-label treatment phase)

Search NIH Clinical Center for Hematologic Cancer

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hematologic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hematologic Cancer:
ALD-151, umbilical cord blood cells for hematologic and immunodefeciency diseases
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Co-infusion of umbilical cord blood and haploidentical CD34+ cells for hematological diseases
Ducord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Expanded cord blood hematopoietic stem cells for hematologic malignancies
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx, umbilical cord blood stem/progenitor cells for hematological diseases
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Embryonic/Adult Cultured Cells Related to Hematologic Cancer:
Umbilical cord blood ALDH+ cells (ALD-151) PMIDs: 10430905
Umbilical cord blood-derived hematopoietic progenitor cells (Allocord) PMIDs: 11953027
Peripheral blood-derived hematopoietic stem cells
Umbilical cord blood-derived hematopoietic progenitor cells (Ducord) PMIDs: 22698485 21810098 21277377 23711284
Expanded umbilical cord blood-derived hematopoietic stem cells PMIDs: 21396596
Mesenchymal Precursor Cells (STRO-3 selected) PMIDs: 21396596
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 20676147

Cochrane evidence based reviews: hematologic neoplasms

Genetic Tests for Hematologic Cancer

Genetic tests related to Hematologic Cancer:

# Genetic test Affiliating Genes
1 Hematologic Neoplasm 28 H3C2

Anatomical Context for Hematologic Cancer

Organs/tissues related to Hematologic Cancer:

MalaCards : Bone Marrow, T Cells, Bone, Myeloid, Nk Cells, Endothelial, Breast

Publications for Hematologic Cancer

Articles related to Hematologic Cancer:

(show top 50) (show all 16650)
# Title Authors PMID Year
1
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. 62 5
25581430 2015
2
CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN. 5
23696637 2013
3
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. 5
18971950 2009
4
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. 5
16834459 2006
5
An update on molecular genetics of gastrointestinal stromal tumours. 5
16731599 2006
6
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. 5
11526490 2001
7
FMS mutations in myelodysplastic, leukemic, and normal subjects. 5
2406720 1990
8
The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. 53 62
20406947 2010
9
Bloodstream infections caused by qnr-positive Enterobacteriaceae: clinical and microbiologic characteristics and outcomes. 53 62
20227228 2010
10
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. 53 62
20371442 2010
11
Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. 53 62
19961944 2010
12
Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices. 53 62
20214447 2010
13
PAX5 expression in nonhematopoietic tissues. Reappraisal of previous studies. 53 62
20154279 2010
14
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. 53 62
20053713 2010
15
The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings. 53 62
19857587 2010
16
Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10. 53 62
20127944 2010
17
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. 53 62
19861438 2009
18
Molecular monitoring of 8p11 myeloproliferative syndrome in an infant. 53 62
19829149 2009
19
Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. 53 62
19773259 2009
20
Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. 53 62
19387466 2009
21
Expression of VEGF and VEGF receptors in childhood precursor B-cell acute lymphoblastic leukemia evaluated by immunohistochemistry. 53 62
19707156 2009
22
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. 53 62
19546476 2009
23
HDAC expression and clinical prognosis in human malignancies. 53 62
19103471 2009
24
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. 53 62
19447617 2009
25
[Histone modification and its application in therapy for hematologic malignancies -- review]. 53 62
19549415 2009
26
Plasma levels of FL and SDF-1 and expression of FLT-3 and CXCR4 on CD34+ cells assessed pre and post hematopoietic stem cell mobilization in patients with hematologic malignancies and in healthy donors. 53 62
19380254 2009
27
What is the role for donor natural killer cells after nonmyeloablative conditioning? 53 62
19361750 2009
28
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. 53 62
19190243 2009
29
Increased expression of p63 and survivin in cholesteatomas. 53 62
18615329 2009
30
Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies. 53 62
19216843 2009
31
The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia. 53 62
18987662 2009
32
Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. 53 62
19760074 2009
33
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. 53 62
19344187 2009
34
Jumping translocations in hematological malignancies: a cytogenetic study of five cases. 53 62
19027489 2008
35
Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome. 53 62
18799937 2008
36
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models. 53 62
18708365 2008
37
The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. 53 62
18373639 2008
38
TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. 53 62
18535006 2008
39
[The significance of dynamic detection of WT1 expression on patients of hematologic malignancy following allogeneic hematopoietic stem cell transplantation]. 53 62
19035171 2008
40
The tyrosine phosphatase Shp2 (PTPN11) in cancer. 53 62
18286234 2008
41
The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. 53 62
18538168 2008
42
Beyond the increasing complexity of the immunomodulatory HLA-G molecule. 53 62
18334671 2008
43
Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. 53 62
18177485 2008
44
Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign. 53 62
18336085 2008
45
ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. 53 62
18281529 2008
46
[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets]. 53 62
18729264 2008
47
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. 53 62
18437899 2008
48
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. 53 62
18056455 2007
49
A novel gene, ANKRD28 on 3p25, is fused with NUP98 on 11p15 in a cryptic 3-way translocation of t(3;5;11)(p25;q35;p15) in an adult patient with myelodysplastic syndrome/acute myelogenous leukemia. 53 62
17988990 2007
50
The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature. 53 62
18632516 2007

Variations for Hematologic Cancer

ClinVar genetic disease variations for Hematologic Cancer:

5 (show all 14)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 ETV6 NM_001987.5(ETV6):c.1195C>T (p.Arg399Cys) SNV Pathogenic
162220 rs724159945 GRCh37: 12:12038902-12038902
GRCh38: 12:11885968-11885968
2 ETV6 NM_001987.5(ETV6):c.1106G>A (p.Arg369Gln) SNV Pathogenic
162221 rs724159946 GRCh37: 12:12037475-12037475
GRCh38: 12:11884541-11884541
3 ETV6 NM_001987.5(ETV6):c.641C>T (p.Pro214Leu) SNV Likely Pathogenic
162222 rs724159947 GRCh37: 12:12022535-12022535
GRCh38: 12:11869601-11869601
4 CSF1R NM_001288705.3(CSF1R):c.1711T>G (p.Tyr571Asp) SNV Likely Pathogenic
376166 rs1057519802 GRCh37: 5:149441328-149441328
GRCh38: 5:150061765-150061765
5 CSF1R NM_001288705.3(CSF1R):c.903G>T (p.Leu301Phe) SNV Likely Pathogenic
376703 rs1057520014 GRCh37: 5:149453043-149453043
GRCh38: 5:150073480-150073480
6 CSF1R NM_001288705.3(CSF1R):c.2905T>C (p.Tyr969His) SNV Likely Pathogenic
376272 rs121913393 GRCh37: 5:149433646-149433646
GRCh38: 5:150054083-150054083
7 CSF1R NM_001288705.3(CSF1R):c.2906A>T (p.Tyr969Phe) SNV Likely Pathogenic
Likely Pathogenic
376270 rs1801271 GRCh37: 5:149433645-149433645
GRCh38: 5:150054082-150054082
8 CSF1R NM_001288705.3(CSF1R):c.902T>C (p.Leu301Ser) SNV Likely Pathogenic
376273 rs121913390 GRCh37: 5:149453044-149453044
GRCh38: 5:150073481-150073481
9 CBL NM_005188.4(CBL):c.1150T>C (p.Cys384Arg) SNV Likely Pathogenic
29822 rs387906664 GRCh37: 11:119148930-119148930
GRCh38: 11:119278220-119278220
10 KIT NM_000222.3(KIT):c.2446G>C (p.Asp816His) SNV Likely Pathogenic
Likely Pathogenic
13863 rs121913506 GRCh37: 4:55599320-55599320
GRCh38: 4:54733154-54733154
11 KIT NM_000222.3(KIT):c.2447A>T (p.Asp816Val) SNV Likely Pathogenic
13852 rs121913507 GRCh37: 4:55599321-55599321
GRCh38: 4:54733155-54733155
12 MPL NM_005373.3(MPL):c.1544G>T (p.Trp515Leu) SNV Likely Pathogenic
14164 rs121913615 GRCh37: 1:43815009-43815009
GRCh38: 1:43349338-43349338
13 KIT NM_000222.3(KIT):c.1924A>G (p.Lys642Glu) SNV Likely Pathogenic
13866 rs121913512 GRCh37: 4:55594221-55594221
GRCh38: 4:54728055-54728055
14 CBL NM_005188.4(CBL):c.1111T>C (p.Tyr371His) SNV Likely Pathogenic
13811 rs267606706 GRCh37: 11:119148891-119148891
GRCh38: 11:119278181-119278181

Expression for Hematologic Cancer

Search GEO for disease gene expression data for Hematologic Cancer.

Pathways for Hematologic Cancer

Pathways related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 RUNX1 NUP98 KIT JAK2 H3C2 FLT3
2
Show member pathways
13.62 ABL1 CBL CSF1R CSF3 FLT3 H3C2
3 13.48 ABL1 CBL FLT3 H3C2 IL3 JAK2
4
Show member pathways
13.35 MPL KIT JAK2 IL3 H3C2 FLT3
5
Show member pathways
13 NUP98 JAK2 IL3 H3C2 FLT3 CSF3
6
Show member pathways
12.69 KIT JAK2 IL3 FLT3 CSF3 CSF1R
7
Show member pathways
12.49 KIT JAK2 IL3 CSF1R ABL1
8
Show member pathways
12.21 KIT IL3 FLT3 CSF1R CBL
9 12.15 RUNX1 MPL KIT JAK2 IL3 CBL
10 12.04 KIT FLT3 CSF1R ABL1
11
Show member pathways
11.85 KIT JAK2 CBL
12
Show member pathways
11.76 KIT JAK2 CBL
13
Show member pathways
11.71 KIT FLT3 CSF1R
14 11.58 KIT FLT3 CSF1R
15 11.42 MPL KIT IL3 FLT3 CSF3
16 11.31 KIT IL3 CSF1R
17 11.27 JAK2 CSF1R ABL1
18 11.27 KIT JAK2 FLT3 CSF1R CBL ABL1
19 11.19 JAK2 H3C2 ABL1
20 10.86 CSF1R CSF3 FLT3 IL3 KIT
21 10.73 KIT CSF1R ABL1
22
Show member pathways
10.59 RUNX1 IL3

GO Terms for Hematologic Cancer

Biological processes related to Hematologic Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.21 PTHLH MPL KIT JAK2 IL3 FLT3
2 protein autophosphorylation GO:0046777 10.18 KIT JAK2 FLT3 CSF1R ABL1
3 peptidyl-tyrosine phosphorylation GO:0018108 10.13 KIT JAK2 FLT3 CSF1R ABL1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.11 JAK2 IL3 CSF3 ABL1
5 cellular response to cytokine stimulus GO:0071345 10.01 FLT3 CSF3 CSF1R
6 regulation of cell population proliferation GO:0042127 9.97 KIT FLT3 CSF1R ABL1
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.96 KIT JAK2 FLT3 CSF3 CBL
8 embryonic hemopoiesis GO:0035162 9.93 KMT2A KIT IL3
9 myeloid progenitor cell differentiation GO:0002318 9.86 KIT FLT3
10 hemopoiesis GO:0030097 9.85 CSF1R FLT3 KIT MPL RUNX1
11 positive regulation of extracellular matrix organization GO:1903055 9.83 RUNX1 ABL1
12 regulation of cardiac muscle cell proliferation GO:0060043 9.72 RUNX1 MIR199A1
13 regulation of connective tissue replacement GO:1905203 9.67 MIR199A1 RUNX1
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 KIT JAK2 IL3 FLT3 CSF1R
15 positive regulation of response to stimulus GO:0048584 9.58 CSF1R FLT3 KIT
16 positive regulation of protein modification process GO:0031401 9.5 KIT FLT3 CSF1R
17 cytokine-mediated signaling pathway GO:0019221 9.47 MPL KIT JAK2 FLT3 CSF3 CSF1R

Molecular functions related to Hematologic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 KIT FLT3 CSF1R
2 peptide hormone receptor binding GO:0051428 9.56 PTHLH JAK2
3 SH2 domain binding GO:0042169 9.43 KIT JAK2 ABL1
4 protein tyrosine kinase activity GO:0004713 9.32 KIT JAK2 FLT3 CSF1R ABL1

Sources for Hematologic Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....